Sandoz buys inhalable generics developer Oriel Therapeutics
This article was originally published in Scrip
Executive Summary
Sandoz has acquired the privately held Oriel Therapeutics, gaining exclusive rights to the US firm's portfolio of inhalable generic drug candidates. The deal gives Sandoz three development projects as well as Oriel's novel FreePath drug delivery system and Solis multi-dose drug powder inhaler.